Here are seven things to know:
1. The offering included 750,000 shares from the company and 3.75 million shares from selling stockholders.
2. The public price was $22.60 per share.
3. The underwriter has 30 days to purchase up to 675,000 additional shares from the company and selling stockholders on a pro rata basis.
4. Net proceeds from the offering were around $16.3 million after deducting the underwriting discount and estimated offering expenses.
5. The proceeds will go toward working capital and general corporate proposes, including expanding K2M’s global distribution network and purchase inventory to support sales efforts.
6. In the future, the company could use the proceeds for an acquisition or investment in complementary products, technologies or businesses.
7. Barclays was the sole book-running manager and underwriter for the offering.
More articles on orthopedic devices:
Medtronic to acquire RF Surgical Systems: 6 key notes
4 notes on Stryker Spine’s LITe ALIF Procedural Solution
Rivanna Medcial’s Accuro receives FDA clearance
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
